CATCHWORDS
CORPORATIONS - allotment or issue of securities where prospectus indicates application for quotation on stock market - allotment or issue void and corporation obliged to repay if permission for quotation not granted within stipulated period - permission granted subject to compliance with the requirements - undertaking in writing by directors of corporation to comply with requirements of securities exchange - construction of s. 1031 of Corporations Law.
Corporations Law ss. 1031, 1084, 1322.
PREMIER PACIFIC PHARMACEUTICAL INDUSTRIES LIMITED v
AUSTRALIAN STOCK EXCHANGE LIMITED & ANOR
No. NG 3147 of 1995
BEFORE: GUMMOW J.
PLACE: SYDNEY.
DATE: 19 APRIL 1995.
IN THE FEDERAL COURT OF AUSTRALIA )
NEW SOUTH WALES DISTRICT REGISTRY ) No. NG 3147 of 1995
GENERAL DIVISION )
BETWEEN: PREMIER PACIFIC PHARMACEUTICAL
INDUSTRIES LIMITED
(ARBN 066 346 889)
Applicant
AND: AUSTRALIAN STOCK EXCHANGE LIMITED
(ACN 008 624 691)
First Respondent
ABN AMRO BANK NV
Second Respondent
BEFORE: GUMMOW J.
PLACE: SYDNEY.
DATE: 19 APRIL 1995.
MINUTE OF ORDERS
THE COURT ORDERS THAT:
(1)The order made 3 April 1995 be extended by deleting the words "two days after the delivery of judgment in these proceedings" and inserting "27 April 1995".
(2)The applicant pay the costs of the respondents of the application and the cross-claim.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA )
NEW SOUTH WALES DISTRICT REGISTRY ) No. NG 3147 of 1995
GENERAL DIVISION )
BETWEEN: PREMIER PACIFIC PHARMACEUTICAL
INDUSTRIES LIMITED
(ARBN 066 346 889)
Applicant
AND: AUSTRALIAN STOCK EXCHANGE LIMITED
(ACN 008 624 691)
First Respondent
ABN AMRO BANK NV
Second Respondent
BEFORE: GUMMOW J.
PLACE: SYDNEY.
DATE: 19 APRIL 1995.
REASONS FOR JUDGMENT
The applicant, Premier Pacific Pharmaceutical Industries Limited ("Premier Pacific") is incorporated in Bermuda. It has an 80% interest in two Sino-foreign equity joint ventures established in the People's Republic of China ("the PRC"). The remaining 20% interest in the two equity joint ventures is owned by Tianjin Holdings, a State-owned corporation.
The first of the joint ventures owns an enterprise known as "Tianjin Medical", which is one of the largest wholesalers of pharmaceutical products in the PRC. A wholly owned subsidiary of Tianjin Medical has a 20% shareholding in TSKF,
a Sino-American equity joint venture which manufactures and markets SmithKline Beecham pharmaceutical products in the PRC. TSKF is the second largest manufacturer in the PRC of ethical and "over the counter" pharmaceutical products.
The second joint venture owns an enterprise known as Hebei Pharmaceutical, which is a manufacturer of the raw material Vitamin B2 and of the anti-cancer drug Bleomycin A5. Hebei Pharmaceutical manufactures both for the local market in the PRC and for export.
The Prospectus
On 30 November 1994, the directors of Premier Pacific signed a prospectus in relation to an offer of 40m ordinary shares of $A0.20 each to be issued in the authorised, but unissued, share capital of Premier Pacific at an issue price of $A1 each.
On 1 December…
Keep reading for free
Create a free CaseChat account to read Premier Pacific Pharmaceutical Industries Ltd v Australian S... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [1995] FCA 242
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi